Annual Accounts Payable
$1.01 M
-$235.00 K-18.92%
March 1, 2024
Summary
- As of February 8, 2025, GRCE annual accounts payable is $1.01 million, with the most recent change of -$235.00 thousand (-18.92%) on March 1, 2024.
- During the last 3 years, GRCE annual accounts payable has risen by +$892.00 thousand (+775.65%).
- GRCE annual accounts payable is now -66.95% below its all-time high of $3.05 million, reached on March 1, 2019.
Performance
GRCE Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Payable
$1.68 M
+$126.00 K+8.13%
September 1, 2024
Summary
- As of February 8, 2025, GRCE quarterly accounts payable is $1.68 million, with the most recent change of +$126.00 thousand (+8.13%) on September 1, 2024.
- Over the past year, GRCE quarterly accounts payable has increased by +$762.00 thousand (+83.46%).
- GRCE quarterly accounts payable is now -85.93% below its all-time high of $11.90 million, reached on June 1, 2019.
Performance
GRCE Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Payable Formula
Accounts Payable = Beginning Accounts Payable + Purchases on Credit − Payments to Suppliers
GRCE Accounts Payable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -18.9% | +83.5% |
| 3 y3 years | +775.6% | -55.1% |
| 5 y5 years | -67.0% | -83.5% |
GRCE Accounts Payable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -40.0% | +775.6% | -55.1% | +175.9% |
| 5 y | 5-year | -67.0% | +775.6% | -82.3% | +1356.5% |
| alltime | all time | -67.0% | +1179.5% | -85.9% | +2028.3% |
Grace Therapeutics Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $1.68 M(+8.1%) |
| Jun 2024 | - | $1.55 M(+53.8%) |
| Mar 2024 | $1.01 M(-18.9%) | $1.01 M(+10.3%) |
| Dec 2023 | - | $913.00 K(+33.3%) |
| Sep 2023 | - | $685.00 K(+12.9%) |
| Jun 2023 | - | $607.00 K(-51.1%) |
| Mar 2023 | $1.24 M(-26.0%) | $1.24 M(-63.0%) |
| Dec 2022 | - | $3.36 M(-10.0%) |
| Sep 2022 | - | $3.73 M(+22.0%) |
| Jun 2022 | - | $3.06 M(+82.5%) |
| Mar 2022 | $1.68 M(+1359.1%) | $1.68 M(-41.0%) |
| Dec 2021 | - | $2.84 M(-35.9%) |
| Sep 2021 | - | $4.43 M(+94.5%) |
| Jun 2021 | - | $2.28 M(+1881.7%) |
| Mar 2021 | $115.00 K(-93.3%) | $115.00 K(-94.6%) |
| Dec 2020 | - | $2.14 M(-41.6%) |
| Sep 2020 | - | $3.67 M(-37.8%) |
| Jun 2020 | - | $5.90 M(+244.4%) |
| Mar 2020 | $1.71 M(-43.8%) | $1.71 M(-81.9%) |
| Dec 2019 | - | $9.45 M(-7.0%) |
| Sep 2019 | - | $10.16 M(-14.6%) |
| Jun 2019 | - | $11.90 M(+290.6%) |
| Mar 2019 | $3.05 M(+15.1%) | $3.05 M(-70.0%) |
| Dec 2018 | - | $10.17 M(-0.3%) |
| Sep 2018 | - | $10.20 M(+30.9%) |
| Jun 2018 | - | $7.79 M(+194.2%) |
| Mar 2018 | $2.65 M | $2.65 M(-33.4%) |
| Dec 2017 | - | $3.97 M(+48.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2017 | - | $2.68 M(+79.6%) |
| Jun 2017 | - | $1.49 M(+14.9%) |
| Mar 2017 | $194.20 K(-29.8%) | - |
| Nov 2016 | - | $1.30 M(+25.0%) |
| Aug 2016 | - | $1.04 M(-9.1%) |
| May 2016 | - | $1.14 M(+313.2%) |
| Feb 2016 | $276.70 K(+40.5%) | $276.70 K(-76.8%) |
| Nov 2015 | - | $1.19 M(+45.9%) |
| Aug 2015 | - | $816.30 K(-15.4%) |
| May 2015 | - | $964.50 K(+389.6%) |
| Feb 2015 | $197.00 K(-31.4%) | $197.00 K(-82.0%) |
| Nov 2014 | - | $1.10 M(-15.8%) |
| Aug 2014 | - | $1.30 M(-16.2%) |
| May 2014 | - | $1.55 M(+440.3%) |
| Feb 2014 | $287.30 K(-9.5%) | $287.30 K(-85.8%) |
| Nov 2013 | - | $2.02 M(+57.3%) |
| Aug 2013 | - | $1.29 M(+107.9%) |
| May 2013 | - | $618.90 K(+94.9%) |
| Feb 2013 | $317.60 K(-42.5%) | $317.60 K(-64.8%) |
| Nov 2012 | - | $901.80 K(+8.4%) |
| Aug 2012 | - | $832.00 K(+4.0%) |
| May 2012 | - | $800.00 K(+44.8%) |
| Feb 2012 | $552.40 K(+209.5%) | $552.40 K(-21.8%) |
| Nov 2011 | - | $706.70 K(-27.6%) |
| Aug 2011 | - | $976.60 K(+51.0%) |
| May 2011 | - | $646.90 K(+262.4%) |
| Feb 2011 | $178.50 K(+126.8%) | $178.50 K(+126.8%) |
| Feb 2010 | $78.70 K | $78.70 K |
FAQ
- What is Grace Therapeutics annual accounts payable?
- What is the all time high annual accounts payable for Grace Therapeutics?
- What is Grace Therapeutics annual accounts payable year-on-year change?
- What is Grace Therapeutics quarterly accounts payable?
- What is the all time high quarterly accounts payable for Grace Therapeutics?
- What is Grace Therapeutics quarterly accounts payable year-on-year change?
What is Grace Therapeutics annual accounts payable?
The current annual accounts payable of GRCE is $1.01 M
What is the all time high annual accounts payable for Grace Therapeutics?
Grace Therapeutics all-time high annual accounts payable is $3.05 M
What is Grace Therapeutics annual accounts payable year-on-year change?
Over the past year, GRCE annual accounts payable has changed by -$235.00 K (-18.92%)
What is Grace Therapeutics quarterly accounts payable?
The current quarterly accounts payable of GRCE is $1.68 M
What is the all time high quarterly accounts payable for Grace Therapeutics?
Grace Therapeutics all-time high quarterly accounts payable is $11.90 M
What is Grace Therapeutics quarterly accounts payable year-on-year change?
Over the past year, GRCE quarterly accounts payable has changed by +$762.00 K (+83.46%)